Doc code :IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-08)
Approved for use through 06/30/2008. OMB 0651-0031
Ormation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	10642844
	2003-08-18
Lewy	
	1614
Royds	, Leslie A.
er	90-559-T
	Royds

U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Da	ate	of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1									
If you wish to add additional U.S. Patent citation information please click the Add button.										
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publicat Date	ion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines wher int Passages or Rele s Appear	
	1									
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Add	d button	Add	
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Kind Code <sup>2</sup> j		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines vhere Relevant Passages or Relevan Figures Appear	T5	
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*  Cite No  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10642844	
Filing Date		2003-08-18	
First Named Inventor	Lewy		
Art Unit		1614	
Examiner Name	Royds, Leslie A.		
Attorney Docket Number		90-559-T	

1	ARAI et al. "Isoflurane increases, but sevoflurane decreases blood concentrations of melatonin in women," Journal of Anesthesiology 18(3):228-31 (2004).	
2	DAVIES et al. "Mapping the Melatonin Receptor. 5. Melatonin Agonists and Antagonists Derived from Tetrahydrocyclopent[b]indoles, Tetrahydrocarbazoles and Hexahydro cyclopent[b]indoles," Journal of Medicinal Chemistry 41(4):451-67 (1998).	
3	DEMISCH "Melatonin and cortisol increase after fluvoxamine [letter]," British Journal of Clinical Pharmacology 22(5): 620-22 (1986).	
4	DESIR et al. "Ritodrine increases plasma melatonin in women," Lancet 1(8317):184-85 (1983).	
5	GARDEET al. "8-methoxypsoralen increases daytime plasma melatonin levels in humans through inhibition of metabolism," Photochemistry and Photobiology 60(5):475-80 (1994).	
6	GARRATT et al. (1995). "Mapping the Melatonin Receptor. 3. Design and Synthesis of Melatonin Agonists and Antagonists Derived from 2-phenyltryptamines," Journal of Medicinal Chemistry 38(7):1132-39.	
7	GROTA et al. "Psoralen increases melatonin levels without ultraviolet light." Annals of the New York Academy of Sciences 453:385-87(1985).	
8	KRAUCHI et al. "Evidence for a phase advance in circadian temperature regulation after acute melatonin and a melatonin agonist (S-20098)," Sleep Research 24: 526 (1995).	
9	LE GOUIC et al. "Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake of the garden dormouse," International Journal of Obesity 20(7): 661-67(1996).	
10	MARTINET et al. "Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent," Pharmacology Biochemistry and Behavior 54:713-18 (1996).	
11	MATHE-ALLAINMAT et al. "Synthesis of 2-amido-2,3-dihydro-1H-phenelene derivatives as new conformationally restricted ligands for melatonin receptors," Journal of Medicinal Chemistry 39(16): 3089-95 (1996).	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10642844	
Filing Date		2003-08-18	
First Named Inventor	Lewy		
Art Unit		1614	
Examiner Name	Royds, Leslie A.		
Attorney Docket Number		90-559-T	

<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
Examiner Signa	ature	Date Considered						
EXAMINER SIGNATURE								
If you wish to a	dd add	itional non-patent literature document citation information please click the Add b	utton Add					
19		TARZIA et al. "1-(2-Alkaneamidoethyl)-6-methoxyindole deriviatives: A new class of potent indole melatonin analogues. Evaluation of the biological activity," Journal of Medicinal Chemistry 40(13):2003-10 (1997).						
18	TARZIA at al. "Design and synthesis of melatonin receptor agonists and antagonists," Farmaco 55(3):184-87(2000).							
17		SPASONI et al. "2-Substituted 5-methoxy-Nacyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity," Journal of Medicinal Chemistry 36(25):4069-74 (1993).						
16		SOUETRE et all. "5-Methoxypsoralen increases the plasma melatonin levels in humans," Journal of Investigative Dermatology 89(2):152-55 (1987).						
15		SACK "Desmethylimipramine treatment increases melatonin production in humans," Biological Psychiatry 21:406-10 (1986).						
14		REDMAN et al. "Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms," Psychopharmacology (Berl) 118(4):385-90 (1995).						
13		PALAZIDOU et al. "Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients," Psychological Medicine 22(2):309-15 (1992).						
12	OXENKRUGET al. "Single dose of tranylcypromine increases human plasma melatonin," Biological Psychiatry 21: 1081-85 (1986).							